GSK has developed a new propellant technology for inhaler devices that drastically reduces their use of greenhouse gases, which perhaps surprisingly account for nearly half (49%) of the group’s ...

GSK GSK stock has risen 18.5% so far this year compared with an increase of 27.1% for the industry. The stock has also been ...

But succour came when her consultant, eight years ago, prescribed an asthma preventer, Seretide Diskus inhaler, with zero side effects. However, following the exit of GSK last year, and the ...

Boehringer Ingelheim GmbH’s and Astrazeneca plc’s implementation of a $35 monthly U.S. price cap on inhalers for asthma and chronic obstructive pulmonary disease is adding to the pressure on Prasco ...

CEO Emma Walmsley's bet on infectious disease drugs and vaccines, including new blockbuster respiratory syncytial virus (RSV) vaccine Arexvy, has been paying off as GSK faces a combination of ...

GSK is a pharmaceutical company with key segments in specialty medicine, general medicine, and vaccines. Economic uncertainties arise from political forces, inflation rates and signs of a ...

Innoviva is focused on critical care and infectious disease therapeutics, with revenue from GSK royalties. Check out why I'm neutral on INVA stock.

Inhalers prescribed to Centers for Medicare & Medicaid Services (CMS) beneficiaries for asthma and chronic obstructive ...

Please read this leaflet carefully before you start using TRELEGY ELLIPTA. This leaflet answers some common questions about TRELEGY ELLIPTA. It does not contain all the available information.

Biologic drugs for asthma may be initiated or continued while conceiving or during pregnancy or breastfeeding following ...